Discussion of interest, page-3

I did Blane. Did you see this article?

https://www.nasdaq.com/article/3-gene-therapy-stocks-investors-can-bet-on-in-rest-of-2018-cm990310

Looks like the market thinks this was a good deal for Axovant (up 8% and rising) overnight but just "'cash for the boys for Benitec". $10 million is the shortfall in the entitlements offer (at .17 cents) and perhaps Nant's way of securing the funding they calculated to need for the cancer trial. Remember how resolved management was about not partnering OPMD but rather taking it through to trials themselves. This may be why Greg West and David Suhy resigned. The timing of all these developments(including Jerel's ascendancy to executive chairman) is very telling. Now with years before we see encouraging OPMD clinical data (and milestones) we are left with Nant's cancer trial. A binary proposition that is no better than a roulette table..